Presentation to be Webcast on April 3 at 4:00 pm ET
WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 27, 2017--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
present at the H.C. Wainwright 1st Annual NASH Investor
Conference in New York on April 3 at 4:00 pm ET. Dr. Luly will present
an overview of Enanta’s wholly-owned research and development programs
with a focus on EDP-305, Enanta’s FXR agonist for non-alcoholic
A live webcast and replay of the presentation will be accessible by
visiting the “Calendar of Events” section on the “Investors” page of
Enanta’s website at www.enanta.com.
The webcast replay will be available following the presentation and will
be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs for viral
infections and liver diseases. Enanta’s research and development efforts
are currently focused on the following disease targets: non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory
syncytial virus (RSV) and hepatitis B virus (HBV).
Enanta has discovered novel protease inhibitors for use against the
hepatitis C virus (HCV). These protease inhibitors, developed through
Enanta’s collaboration with AbbVie, include paritaprevir, currently
marketed in AbbVie’s HCV regimens, and glecaprevir (ABT-493), Enanta’s
second protease inhibitor product, which AbbVie is developing as part of
its investigational HCV regimen of glecaprevir/pibrentasvir (G/P) now in
registration in the U.S., the E.U. and Japan. Royalties and any further
milestone payments from this collaboration will provide funding for
Enanta’s earlier development programs, including its Phase 1 FXR agonist
program for NASH/PBC, and its preclinical programs for HBV and RSV.
Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170327005800/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
MacDougall Biomedical Communications